Charles River Laboratories International, Inc. (NYSE:CRL) Receives $209.46 Consensus Price Target from Analysts

Shares of Charles River Laboratories International, Inc. (NYSE:CRL) have been given an average recommendation of “Moderate Buy” by the fifteen ratings firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation and ten have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $209.4615.

CRL has been the topic of several analyst reports. Mizuho set a $215.00 target price on Charles River Laboratories International in a research report on Friday, January 9th. Barclays lifted their price target on shares of Charles River Laboratories International from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, December 15th. Citigroup raised their price objective on shares of Charles River Laboratories International from $200.00 to $265.00 and gave the stock a “buy” rating in a report on Friday, January 16th. TD Cowen reissued a “buy” rating on shares of Charles River Laboratories International in a research report on Thursday, January 22nd. Finally, Robert W. Baird set a $224.00 price target on shares of Charles River Laboratories International in a research report on Friday, January 9th.

Hedge Funds Weigh In On Charles River Laboratories International

Several large investors have recently added to or reduced their stakes in the company. Tema Etfs LLC bought a new position in Charles River Laboratories International in the 4th quarter worth about $26,000. Cromwell Holdings LLC grew its holdings in Charles River Laboratories International by 542.9% in the 2nd quarter. Cromwell Holdings LLC now owns 180 shares of the medical research company’s stock worth $27,000 after buying an additional 152 shares in the last quarter. Rothschild Investment LLC increased its position in Charles River Laboratories International by 82.4% in the 3rd quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 84 shares during the period. Neo Ivy Capital Management acquired a new position in Charles River Laboratories International during the 2nd quarter worth $29,000. Finally, Atlantic Union Bankshares Corp bought a new position in shares of Charles River Laboratories International in the third quarter worth $31,000. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Stock Performance

Charles River Laboratories International stock opened at $211.94 on Friday. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.37 and a quick ratio of 1.10. The firm’s fifty day moving average price is $201.38 and its 200 day moving average price is $177.88. The company has a market capitalization of $10.43 billion, a price-to-earnings ratio of -135.86, a price-to-earnings-growth ratio of 6.51 and a beta of 1.61. Charles River Laboratories International has a 12-month low of $91.86 and a 12-month high of $228.88.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, November 5th. The medical research company reported $2.43 earnings per share for the quarter, beating the consensus estimate of $2.32 by $0.11. Charles River Laboratories International had a positive return on equity of 15.78% and a negative net margin of 2.07%.The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $990.43 million. During the same period last year, the firm earned $2.59 earnings per share. The company’s revenue was down .5% on a year-over-year basis. On average, research analysts forecast that Charles River Laboratories International will post 9.36 EPS for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.